What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.
Why Scilex Holding Company sees strategic optionality in diagnostic platforms beyond traditional therapeutics
Explore what Scilex Holding Company’s $20M Quantum Scan investment means for preventive diagnostics and the execution risks ahead.
Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.
Sixty Degrees Pharmaceuticals bets on purification science to unlock castanospermine commercialization
Find out how Sixty Degrees Pharmaceuticals is repositioning castanospermine through a botanical pathway and what regulatory and manufacturing risks still remain.
Tinlarebant moves closer to FDA review after Belite Bio finishes DRAGON II trial enrollment
Find out how Belite Bio’s DRAGON II milestone moves tinlarebant closer to FDA review as a potential first therapy for Stargardt disease.
Cognition Therapeutics advances regulatory strategy for zervimesine in an underserved neurodegenerative disease
Cognition Therapeutics aligns with FDA on zervimesine Phase 2b plans. Discover what this means for dementia with Lewy bodies drug development.
What Cloudbreak Pharma’s Phase 2 FDA meeting reveals about late-stage risk in ophthalmic drug development
Find out how Cloudbreak Pharma’s Phase 2 FDA meeting reshapes late-stage risk for CBT-004 and what it signals for ophthalmic drug development.
Imviva Biotech secures FDA orphan designation as CD7 CAR-T development faces execution challenges
FDA grants orphan drug designation to Imviva Biotech’s CTD402. Find out what this means for allogeneic CAR-T development in T-cell leukemia.
How Arcutis Biotherapeutics’ control of ZORYVE promotion could influence real-world dermatology and pediatric use
Arcutis Biotherapeutics takes full control of ZORYVE promotion. See how this shift could affect real-world dermatology and pediatric prescribing.
Scancell’s late-stage push for iSCIB1+ reframes the risk calculus in advanced melanoma trials
FDA clears Scancell’s iSCIB1+ for Phase 3 testing in advanced melanoma. Discover what this means for immunotherapy risk, trial design, and competition.